posted on 2023-03-30, 22:31authored byHendrika M. Oosterkamp, E. Marielle Hijmans, Thijn R. Brummelkamp, Sander Canisius, Lodewyk F.A. Wessels, Wilbert Zwart, René Bernards
Figure S6. The USP9X knockdown tamoxifen classifier does not predict outcome after adjuvant chemotherapy in ERα positive disease. The USP9X knockdown tamoxifen classifier was tested in a cohort of breast cancer patients (a subset from the 295 patients in the van de Vijver cohort (39)) with ERα positive breast tumors treated with adjuvant chemotherapy only. Kaplan-Meier survival curves for distant metastasis free survival (DMFS) were generated, with p values indicated.